Robert Byrnes
Mr. Byrnes has an extensive background in healthcare as a senior executive with over 45 years of industry experience. Most recently, he served as President and CEO of Thermage, Inc. from 2002 until 2005.

From 1997 to 2002 and from 2005 to the present, Mr. Byrnes has served as President and CEO of Roan, Inc., an advisory service organization for healthcare organizations. He has also served as Chairman and CEO of Tokos Medical Corporation, President of Caremark, Inc., and Vice President of Marketing, Sales, New Business and Clinical Development for Genentech, Inc.

Mr. Byrnes has served as a director on several public healthcare company boards and currently serves on the boards of several privately held medical device, specialty pharmaceutical, and healthcare service organizations. He earned a B.S. in Pharmacy with Honors from Ferris State University and an MBA in Marketing and Finance from Loyola University, Chicago.

Matthew Likens, President and Chief Executive Officer
Mr. Likens joined the company in July of 2006. He began his professional career with the Johnson & Johnson Corporation and spent over twenty years in domestic and international sales, marketing and general management roles at Baxter Healthcare Corporation, culminating in the positions of President of Baxter Biotech North America, then President of their renal business in the U.S. In 2001, Mr. Likens joined GMP Companies, and was President of GMP Wireless Medicine, Inc. This start-up company developed and introduced the LifeSync® System, which is the first Bluetooth®-enabled wireless patient monitoring device, effectively untethering hospitalized patients from bedside monitors. Mr. Likens’ general management experience and intense focus on the customer has led each of his businesses to prominence in its respective market and will be a boon to establishing Ulthera as an industry force. He graduated cum laude from Kent State University with a Bachelor of Business Administration degree with a major in marketing.

Chip Linehan, General Partner, New Enterprise Associates
Mr. Linehan joined NEA in 1992 as an Associate, became a Partner in 1997, and a General Partner in 2004, where he specializes in healthcare investments, including healthcare services, healthcare IT and later stage medical products companies. He participated in the founding and incubation of Bravo Health. Current board memberships include American Pathology Partners, Bravo Health, Elance, Simplex Diabetic Supply, Elements Behavioral Health, Ulthera and Vantage Oncology. Mr. Linehan’s prior board memberships include, among others, CHG Healthcare Services, Atomz, Long Term Care Group and ppoNEXT. In the past, he has also worked closely with AMERIGROUP, AMISYS, Informative and Scandipharm. Chip received a BA (cum laude) from Harvard University.

David Porter, Managing Partner, Apposite Capital
David Porter has over 30 years' experience in private equity and investment banking.
He is Managing Partner of Apposite Capital LLP, an investment firm exclusively focused on healthcare. Apposite invests globally in private companies involved in lifesciences and healthcare services. Prior to co-founding Apposite in 2006, Mr. Porter worked on a number of large LBOs at Nomura's Principal Finance Group including Angel Train Contracts and Married Quarters Estate (now Annington Homes). He then founded and headed Nomura International's healthcare investment and corporate finance groups where he generated consistent high Life sciences returns.

Mr. Porter has extensive involvement in the Healthcare industry; he was a Member of Health Reform reference group for the UK Department of Health, Member of UK government efficiency review on social care, Member of the Myners’ review of Pre-emption and was a Member of the BIA (Bio Industry Association in the UK) Board.

Michael Slayton, Ph.D., Chief Technology Officer and Founder
Dr. Slayton is the founder of both Ulthera, Inc. and its incubator company 15 years earlier, Guided Therapy Systems (GTS). He has over 30 years of senior management and technical responsibility in engineering, development and manufacturing functions, focused primarily on new diagnostic and therapeutic ultrasound applications. Dr. Slayton has helped develop over 70 commercially successful products ranging from electron beam and laser instruments to a variety of ultrasonic systems, scan heads and transducers. He served as Vice President of Advanced Development and Board Member for Dornier MedTech GmbH (a Daimler Benz Company), Phoenix, Arizona; President of Ultrasound Development, Inc., Indianapolis, Indiana; and is currently President and CEO of Ardent Sound, Inc. (formerly GTS, Inc.) and Chairman and CTO for Guided Therapy Systems, LLC and Xthetix, Inc., both Arizona-based companies.   Dr. Slayton has published over 40 technical papers and been awarded 29 patents, with 53 patents pending. He earned an M.S. in Quantum Radiophysics and a Ph.D. in Electrical Engineering from Kiev State University and USSR Academy of Sciences, respectively.